MRNA technical structure shows accumulation after gap and consolidation.

The first arrow, literally in the 99.9 percentile, is Moderna, its code is MRNA. Clearly, this name has become familiar to many of us during the COVID-19 pandemic. Moderna and Pfizer were key names to watch.

But look how this stock rebounded in 2026, and how its rise has accelerated remarkably in the recent period. Six weeks. A large price gap to the upside occurred in mid-August following the approval of a drug, and prices have since consolidated.

So, this is a rare case, where we witnessed a price gap instead of a gap followed by an upward movement or a gap followed by failure, but rather a price gap with a waiting period, another gap with price stability, then prices consolidated and we remained within the range of that gap until the last two sessions.

As this week begins, it seems clear that if we draw a triangle pattern around the recent price movement, we analyzed this pattern last week upwards. So, I like that we saw a price gap upwards, then prices consolidated, and now we see new buyers entering the market, suggesting a new accumulation phase.